Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
01 Communique Laboratory Inc. stock logo
OCQLF
01 Communique Laboratory
$0.05
$0.06
$0.05
$0.22
N/AN/A5,680 shsN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
$63.79
+1.8%
$69.97
$51.79
$89.91
$10.03B1.221.06 million shs185,315 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
01 Communique Laboratory Inc. stock logo
OCQLF
01 Communique Laboratory
-2.38%-2.38%-24.41%-23.39%-63.78%
Bio-Techne Co. stock logo
TECH
Bio-Techne
-1.35%+0.72%-8.39%-13.73%-20.09%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
01 Communique Laboratory Inc. stock logo
OCQLF
01 Communique Laboratory
N/AN/AN/AN/AN/AN/AN/AN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
4.9774 of 5 stars
4.42.01.74.22.62.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
01 Communique Laboratory Inc. stock logo
OCQLF
01 Communique Laboratory
N/AN/AN/AN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
2.80
Moderate Buy$83.9031.53% Upside

Current Analyst Ratings

Latest CBUY, DFX, TECH, OCQLF, and OU1 Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$85.00 ➝ $82.00
2/8/2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$80.00
2/2/2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$92.00 ➝ $87.00
2/2/2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$85.00 ➝ $75.00
2/2/2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$65.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
01 Communique Laboratory Inc. stock logo
OCQLF
01 Communique Laboratory
N/AN/AN/AN/AN/AN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
$1.14B8.82$2.53 per share25.24$12.49 per share5.11

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
01 Communique Laboratory Inc. stock logo
OCQLF
01 Communique Laboratory
N/AN/A0.00N/AN/AN/AN/AN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
$285.26M$1.3846.2235.247.9019.58%14.21%10.36%5/1/2024 (Confirmed)

Latest CBUY, DFX, TECH, OCQLF, and OU1 Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.40N/A-$0.40N/AN/AN/A  
2/1/2024Q2 2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.36$0.33-$0.03$0.49$277.48 million$272.60 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
01 Communique Laboratory Inc. stock logo
OCQLF
01 Communique Laboratory
N/AN/AN/AN/AN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.320.50%+151.98%23.19%N/A

Latest CBUY, DFX, TECH, OCQLF, and OU1 Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/1/2024
Bio-Techne Co. stock logo
TECH
Bio-Techne
quarterly$0.080.5%2/9/20242/12/20242/26/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
01 Communique Laboratory Inc. stock logo
OCQLF
01 Communique Laboratory
N/AN/AN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
0.23
4.37
3.03

Ownership

Institutional Ownership

CompanyInstitutional Ownership
01 Communique Laboratory Inc. stock logo
OCQLF
01 Communique Laboratory
N/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
01 Communique Laboratory Inc. stock logo
OCQLF
01 Communique Laboratory
N/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
4.45%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
01 Communique Laboratory Inc. stock logo
OCQLF
01 Communique Laboratory
N/AN/AN/ANot Optionable
Bio-Techne Co. stock logo
TECH
Bio-Techne
3,050157.19 million150.20 millionOptionable

CBUY, DFX, TECH, OCQLF, and OU1 Headlines

SourceHeadline
BIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAYBIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAY
prnewswire.com - April 26 at 7:00 AM
Bio-Techne Co. (NASDAQ:TECH) Position Raised by Sandhill Capital Partners LLCBio-Techne Co. (NASDAQ:TECH) Position Raised by Sandhill Capital Partners LLC
marketbeat.com - April 25 at 8:07 PM
Bio-Techne loses UK patent bid and heads to UPCBio-Techne loses UK patent bid and heads to UPC
lifesciencesipreview.com - April 25 at 4:19 PM
Court Finds Advanced Cell Diagnostics Patents Invalid in Lawsuit with Molecular InstrumentsCourt Finds Advanced Cell Diagnostics Patents Invalid in Lawsuit with Molecular Instruments
finance.yahoo.com - April 24 at 12:25 PM
Analysts Estimate Techne (TECH) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Techne (TECH) to Report a Decline in Earnings: What to Look Out for
zacks.com - April 24 at 11:07 AM
Bio-Techne (TECH) Scheduled to Post Earnings on WednesdayBio-Techne (TECH) Scheduled to Post Earnings on Wednesday
americanbankingnews.com - April 24 at 4:12 AM
International Assets Investment Management LLC Buys Shares of 12,191 Bio-Techne Co. (NASDAQ:TECH)International Assets Investment Management LLC Buys Shares of 12,191 Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 23 at 4:16 AM
Handelsbanken Fonder AB Purchases 370,000 Shares of Bio-Techne Co. (NASDAQ:TECH)Handelsbanken Fonder AB Purchases 370,000 Shares of Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 22 at 8:51 AM
Kornitzer Capital Management Inc. KS Boosts Holdings in Bio-Techne Co. (NASDAQ:TECH)Kornitzer Capital Management Inc. KS Boosts Holdings in Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 21 at 7:54 AM
Bio-TechneBio-Techne
technologynetworks.com - April 20 at 7:48 PM
Deutsche Bank Aktiengesellschaft Lowers Bio-Techne (NASDAQ:TECH) Price Target to $82.00Deutsche Bank Aktiengesellschaft Lowers Bio-Techne (NASDAQ:TECH) Price Target to $82.00
americanbankingnews.com - April 20 at 4:32 AM
Which Is a Better Investment, Celldex Therapeutics, Inc. or BIO-TECHNE Corp Stock?Which Is a Better Investment, Celldex Therapeutics, Inc. or BIO-TECHNE Corp Stock?
aaii.com - April 19 at 9:13 AM
Which Is a Better Investment, Janux Therapeutics Inc or BIO-TECHNE Corp Stock?Which Is a Better Investment, Janux Therapeutics Inc or BIO-TECHNE Corp Stock?
aaii.com - April 19 at 9:13 AM
Bio-Techne Co. (NASDAQ:TECH) Receives Average Recommendation of "Moderate Buy" from AnalystsBio-Techne Co. (NASDAQ:TECH) Receives Average Recommendation of "Moderate Buy" from Analysts
americanbankingnews.com - April 19 at 4:14 AM
Navigating 4 Analyst Ratings For Bio-TechneNavigating 4 Analyst Ratings For Bio-Techne
markets.businessinsider.com - April 18 at 2:43 PM
Bio-Techne (NASDAQ:TECH) Price Target Cut to $82.00 by Analysts at Deutsche Bank AktiengesellschaftBio-Techne (NASDAQ:TECH) Price Target Cut to $82.00 by Analysts at Deutsche Bank Aktiengesellschaft
marketbeat.com - April 18 at 8:35 AM
Bio-Techne Co. (NASDAQ:TECH) Shares Purchased by Cerity Partners LLCBio-Techne Co. (NASDAQ:TECH) Shares Purchased by Cerity Partners LLC
marketbeat.com - April 18 at 5:39 AM
SVB Wealth LLC Sells 25,151 Shares of Bio-Techne Co. (NASDAQ:TECH)SVB Wealth LLC Sells 25,151 Shares of Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 17 at 7:51 AM
Mackenzie Financial Corp Boosts Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)Mackenzie Financial Corp Boosts Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 16 at 9:27 AM
WCM Investment Management LLC Makes New $1.02 Million Investment in Bio-Techne Co. (NASDAQ:TECH)WCM Investment Management LLC Makes New $1.02 Million Investment in Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 15 at 7:31 AM
Healthcare offers diversification from market hot spotsHealthcare offers diversification from market hot spots
livewiremarkets.com - April 14 at 11:26 PM
Cell Culture Market worth $57.9 billion by 2029 | MarketsandMarkets™Cell Culture Market worth $57.9 billion by 2029 | MarketsandMarkets™
theglobeandmail.com - April 12 at 9:51 AM
BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTSBIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS
prnewswire.com - April 10 at 7:00 AM
New York State Teachers Retirement System Reduces Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)New York State Teachers Retirement System Reduces Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)
marketbeat.com - April 10 at 5:35 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

01 Communique Laboratory logo

01 Communique Laboratory

OTCMKTS:OCQLF
01 Communique Laboratory, Inc. develops and markets remote access solutions. The Company's solutions consist of I'm InTouch, I'm OnCall and I'm InTouch Meeting product lines, which provide users with the ability to conduct online meetings. 01 Communique Laboratory was founded on October 7, 1992 and is headquartered in Toronto, Canada.
Bio-Techne logo

Bio-Techne

NASDAQ:TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.